title: [The results of long-term permixon treatment in patients with symptoms of lower urinary tracts dysfunction due to benign prostatic hyperplasia].
abstract: The trial enrolled 155 patients (mean age 65 years) with documented benign prostatic hyperplasia and lower urinary tracts symptoms (LUTS) (IPSS > 6). All the patients received permixon in a dose 160 mg twice a day for 2 years. The data on 130 patients eligible for assessment were processed statistically by dynamics of IPSS, quality of life (QOL), index of sexual function (MSF-4), size of the prostate, urodynamic and biological parameters which were estimated in 6 (V6), 12 (V12), 18 (V18) and 24 months (V24). Clinical examination with registration of all side effects was made each 3 months. Permixon was found to noticeably reduce IPSS and QOL and increase maximal urine flow speed. The size of the prostate diminished insignificantly. Sexual function remained unchanged for 1 year and improved markedly within the second year (p = 0.001). Permixon had no effect on the level of prostate-specific antigen. Plasma hormones (testosterone, DHT, estradiol, LH, androstendion) did not change. Nine patients developed 10 side effects but they were unrelated to the treatment.
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Pytel'
authors.forename: N A
authors.initials: NA
authors.lastname: Lopatkin
authors.forename: L M
authors.initials: LM
authors.lastname: Gorilovskiĭ
authors.forename: A Z
authors.initials: AZ
authors.lastname: Vinarov
authors.forename: A V
authors.initials: AV
authors.lastname: Sivkov
authors.forename: A A
authors.initials: AA
authors.lastname: Medvedev
mesh_terms: D058891:5-alpha Reductase Inhibitors; D000368:Aged; D000369:Aged, 80 and over; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009031:Moscow; D010936:Plant Extracts / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011788:Quality of Life; D028024:Serenoa; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography; D014555:Urination Disorders / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D014563:Urodynamics / Q000187:drug effects*
chemical_list: D058891:5-alpha Reductase Inhibitors; D004791:Enzyme Inhibitors; D010936:Plant Extracts; C040972:saw palmetto extract